Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Treatment With Myo-inositol on Human Semen Parameters in Patients Undergoing In Vitro Fertilization Cycles

This study has been completed.
Information provided by (Responsible Party):
AGUNCO Obstetrics and Gynecology Centre Identifier:
First received: March 20, 2012
Last updated: March 21, 2012
Last verified: January 2012

Myo-Inositol (MI) is a precursors for the synthesis of phosphatidylinositol polyphosphates (PIPs). In male reproduction, it was shown that MI concentration in the seminiferous tubules is higher than in serum and it was increasing during the movement through the epididymis and the deferent duct. In the present study, the role of myo-inositol has been investigated as a possible antioxidant agent for the systemic treatment of male infertility and the improvement of the sperm's quality.

Samples of seminal fluid were obtained from two groups of patients undergoing to a IVF cycle: healthy subjects and subjects with oligoasthenospermia (OA, < 15 mil/ml). The collected samples were submitted to optic microscopy in order to evaluate semen's volume, spermatozoa's number and motility, during the initial semen analysis and after density gradient separation method; these parameters were evaluated before and after the administration of 4000mg/die of myo-inositol associated to 400 µg of folic acid for three months.

These values were compared with samples of seminal fluid of healthy patients undergoing to a IVF cycle for a female cause of infertility (control group).

Condition Intervention Phase
Sperm Quality
Dietary Supplement: myo-inositol + folic acid
Phase 4

Study Type: Interventional

Resource links provided by NLM:

Further study details as provided by AGUNCO Obstetrics and Gynecology Centre:

Primary Outcome Measures:
  • Semen volume
  • Spermatozoa count
  • Spermatozoa progressive motility
  • Number of spermatozoa after density gradient separation method

Arms Assigned Interventions
Normospermic patients Dietary Supplement: myo-inositol + folic acid
4000mg myo-inositol + 400 µg folic acid
Oligoasthenospermic patients Dietary Supplement: myo-inositol + folic acid
4000mg myo-inositol + 400 µg folic acid
No Intervention: Control


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male

Inclusion Criteria:

  • 3-5 days of sexual abstinence

Exclusion Criteria:

  • systemic and endocrine diseases
  • genital infections
  • history of cryptorchidism or varicocele
  • microorchidism
  • hormonal treatment in the last six months
  • alcohol intake, cigarette smoke and/or drug abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01560065

University of Catania - Department of Surgery - Section of Obstetrics and Gynecology -Center of Physiopathology of Reproduction
Catania, Italy
Sponsors and Collaborators
AGUNCO Obstetrics and Gynecology Centre
  More Information

Responsible Party: AGUNCO Obstetrics and Gynecology Centre Identifier: NCT01560065     History of Changes
Other Study ID Numbers: MI_IVF
Study First Received: March 20, 2012
Last Updated: March 21, 2012

Additional relevant MeSH terms:
Folic Acid
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs
Hematinics processed this record on April 28, 2017